Jul. 9 at 7:56 PM
$MAIA The fog surrounding Phase 2C lifted today, and MAIA will have 6 months worth of efficacy data by year end. Unfortunately the trial started 2-3 months behind schedule, but the overall investment thesis holds. A new trial site in Taiwan began operations too, so hopefully this will allow for faster patient recruitment for Phase 2C/D and Phase 3.
Remaining questions are as follows:
1) When will Phase 3 commence? My guess is that it will start sometime in Q4 2025, maybe even Q1 2026. A little behind schedule, but the investment thesis still holds.
2) New trial sites, such as the one in Taiwan, requires more capital for operations. MAIA's fundraising in 2025 has been significantly less than 2024. We will either need significant fundraising activity in 2H 2025 (potentially 10M shares and 10M warrants, which isn't ideal), or CEO Vitoc will lock in a co-development agreement while the deal-making activity in the industry is elevated.
